teriparatide
Selected indexed studies
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. (Lancet, 2015) [PMID:26144908]
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. (Arch Osteoporos, 2024) [PMID:39312040]
- Teriparatide: a review. (Clin Ther, 2004) [PMID:15262455]
_Worker-drafted node — pending editorial review._
Connections
teriparatide is a side effect of
Sources
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. (2015) pubmed
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. (2024) pubmed
- Teriparatide: a review. (2004) pubmed
- Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. (2019) pubmed
- Teriparatide for severe osteoporosis. (2004) pubmed
- Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials. (2023) pubmed
- Teriparatide in the treatment of osteoporosis. (2008) pubmed
- Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism. (2022) pubmed
- Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients. (2024) pubmed
- Teriparatide for postmenopausal osteoporosis. (2004) pubmed